Positive Results for Moderna's Flu Vaccine Lay Groundwork for Covid Combo Shot
Moderna announced on Monday that its new flu vaccine has shown superior immune response in late-stage trials compared to an existing vaccine. This outcome potentially advances the prospects for Moderna's dual-purpose vaccine tackling both Covid-19 and influenza.
The company had earlier in May been engaging with the FDA, expressing its intention to eventually resubmit its dual vaccine proposal, enhanced by the latest trial results of its flu vaccine alone. The interactions coincide with a significant transformation occurring under Health and Human Services guidance.
Stephen Hoge, Moderna's head of research, mentioned plans to refile for approval of the combo vaccine by year-end and also seek approval for just the flu vaccine. If this is sanctioned, the dual vaccine can proceed. Approvals for both shots are anticipated by next year, regulatory reviews permitting.
The simplicity of a combined vaccine could optimize healthcare efficiency, decrease burdens on medical staff, reduce costs, and increase patient immunization rates.
Moderna currently leads in developing a combination vaccine amid other industry competitors, aiming to penetrate lucrative markets with its offerings against Covid, flu, and other respiratory viruses.
In a major trial involving 40,000+ adults aged 50+, participants were assigned either Moderna's vaccine, mRNA-1010, or a competitor's standard flu shot. Findings indicated Moderna's product was over 26% more effective.
The mRNA-1010 vaccine demonstrated potency against primary flu strains, proving reliable across ages, risk profiles, and flu vaccination histories. For seniors 65+, it outperformed standard vaccines by 27%.
Moderna's CEO underlined these outcomes as significant strides in curbing flu impacts, especially following a notably aggressive recent flu season.
Data suggested the last flu season marked historic highs in hospitalizations and medical visits, underscoring the public health benefits of an improved vaccine.
Safety profiles for the mRNA-1010 vaccine remain consistent with past studies, indicating a stable safety record alongside efficacy.
Despite recent setbacks financially, exacerbated by previous regulatory actions, Moderna remains engaged with the FDA to navigate approval processes effectively.
Hoge expressed confidence in a clearer regulatory pathway ahead concerning the company's flu vaccine developments.



Leave a Reply